Work

Mass balance and metabolite profiles in humans of ACT001, a novel sesquiterpene lactone derivative, using 14 C‐radiolabelled techniques

Year: 2026
Type: article
Abstract: AIMS: ACT001, a novel sesquiterpene lactone derivative, is effective against treating glioblastoma multiforme and other diseases. This study aims to investigate its metabolic and excretion characteristics. METHODS: C]ACT001 was administered to six healthy subjects. Blood, urine and fecal samples were collected and measured for total radioactivity (TRA), ACT001 and its main metabolite (monomethylamine micheliolide, MA-MCL). The safety was also assessed. RESULTS: ) of TRA, of TRA, ACT001 and MA-MCL were 33.7 h, 3.16 h, and 8.45 h, respectively. ACT001 and MA-MCL accounted for 14.49% and 30.50% of TRA, respectively. In addition, radiochromatographic profiling confirmed no other individual metabolite exceeded 2% of total peak area. The individual ratios of total radioactivity in whole blood relative to plasma ranged from 0.330 to 0.827. The primary excretion route of ACT001 was urine (accounting for 90.08% ± 1.16% of dose), with a small amount excreted in faeces (accounting for 7.30% ± 0.66% of dose), resulting in a total excretion rate of 97.39% ± 0.93%. Metabolites represented more than 80% of urinary excretion. The main metabolic pathways involved demethylation, oxidation, and dealkylation to form micheliolide and glucuronidation or cysteine conjugation of related metabolites. CONCLUSIONS: of TRA (33.7 h) vs. ACT001 (3.16 h) and MA-MCL (8.45 h). The overall mass balance was nearly complete. ACT001 and MA-MCL were the primary circulating compounds. Demethylated metabolites were the primary substances excreted in urine and faeces.
Language: English
Field: Chemistry
Open Access status: bronze
OpenAlex ID: W7235691500
FWCI:
Cites: 19
Cited by:
Related to: 10